Whitehawk Therapeutics
WHWK
42 hedge funds and large institutions have $51M invested in Whitehawk Therapeutics in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 11 closing their positions.
75% more capital inflows, than outflows
Capital inflows: $15.2M | Capital outflows: $8.65M
7.61% more ownership
Funds ownership: 56.15% → 63.76% (+7.6%)
0% more funds holding
Funds holding: 42 → 42 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avoro Capital Advisors
New York
|
+$6.85M |
| 2 |
RA Capital Management
Boston,
Massachusetts
|
+$4.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.03M |
| 4 |
Renaissance Technologies
New York
|
+$979K |
| 5 |
Rock Springs Capital Management
Baltimore,
Maryland
|
+$203K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
-$2.67M |
| 2 |
Ikarian Capital
Dallas,
Texas
|
-$1.48M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.29M |
| 4 |
Scion Asset Management
Saratoga,
California
|
-$1.29M |
| 5 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$986K |
WHWK Hedge Fund Activity: Q2 2021 in Review
42 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q2 2021, worth a combined $51M — up 49% from $34.3M a quarter earlier.
Fund positioning in WHWK was balanced in Q2 2021: 11 funds opened new positions, 11 closed out, 7 added to existing stakes and 10 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $6.85M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.67M sold.
- 42 institutional investors held Whitehawk Therapeutics (WHWK) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $51M of Whitehawk Therapeutics stock for Q2 2021, up 49% quarter-over-quarter.
- 11 funds opened new Whitehawk Therapeutics positions in Q2 2021 and 11 closed out, a net change of 0 holders.
- The largest Whitehawk Therapeutics buyer in Q2 2021 was Avoro Capital Advisors, an estimated $6.85M added.
- The largest Whitehawk Therapeutics seller in Q2 2021 was EcoR1 Capital, an estimated $2.67M sold.
Based on aggregated 13F filings for Q2 2021.